Delivery Order SPE2DB20D3101-SPE2DB25FRLX7
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,227.36 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of August 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a single delivery order fulfillment. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and primary pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,534.20 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens on June 26, 2025, with completion scheduled for June 27, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to federal medical procurement needs. The order will be fulfilled at the company's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $1,022.80 to supply Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of August 29, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded through competitive procedures. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under...
- The Defense Logistics Agency awarded a $2,348.65 delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens, with an ultimate completion date of June 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $3,172.50 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL insulin pens on September 9, 2025, with completion targeted for September 10, 2025. This competitive, non-set-aside award utilizes firm fixed pricing and represents a direct fulfillment of pharmaceutical supply needs for the Department of Defense. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,247.31 to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/mL 3mL insulin pens. The contract, awarded on September 5, 2025, with an ultimate completion date of September 8, 2025, was competitively awarded with no set-aside designation. This delivery order operates under a firm fixed price arrangement and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,053.04 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML insulin pens (3ML). The contract is classified as firm fixed price with an ultimate completion date of August 26, 2025, and was competitively awarded with no set-aside designation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $1,348.00 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by August 26, 2025. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lantus SoloStar 100 Unit/ML 3ML insulin pens with a ceiling value of $1,089.70. This competitively awarded, firm fixed-price delivery order was issued on August 15, 2025, with an ultimate completion date of August 18, 2025. The pharmaceutical product will be supplied from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 16, 2025, for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens, with a ceiling value of $1,397.48. This is a firm fixed-price delivery order with no set-aside designation, indicating competitive award. The contract is set to complete by May 19, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under the company's...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRLX7Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $1,022.80 to AmerisourceBergen Drug Corp for the supply of Lantus SoloStar 100 Unit/ML 3ML insulin pens. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded on May 30, 2025, with an ultimate completion date of June 2, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime vendor contract serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The award demonstrates the contractor's continued role in fulfilling critical pharmaceutical procurement requirements for federal medical supply chains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 5/30/25 |